Latest News
Digital Twinning, and how EdgeTI (CTRL.V) is a serious story you’ve never heard of
Bionxt Solutions (BNXT.C): Seeking to confirm national-level cancer drug patent
Why Prospera Energy (PEI.V) might be a transformational investment opportunity in Canadian oil & gas
Sparc AI (SPAI.C) completes development of drone advanced target acquisition system
Plurilock (PLUR.V) lands $19 million deal, largest in their history
Rex Resources (OWN.V) continues gearing up with BC gold property
Medexus Pharmaceuticals (MDP.T) CEO picks up the gauntlet
In today’s episode, Equity.Guru founder, Chris Parry, talks with Ken d’Entremont, CEO and director of Medexus Pharmaceuticals, and asks about the company’s recent strong financials, the possible inclusion of treosulfan into the company’s portfolio and what growth potential investors can expect over the next 12 months.
Enjoy!
Related Posts
Potential of Medexus Pharmaceuticals: Chris Parry gets into what investors are missing
Medexus Pharma (MDP.TO) Breaks Records: A Deep Dive into Quarterly Earnings, Portfolio Growth, and Future Opportunities
Medexus Pharmaceuticals (MDP): A Roller Coaster Ride to Success
Medexus Pharmaceuticals Sets New Revenue Records and Continues Expansion with Innovative Products and Financing
Medexus Pharmaceuticals (MDP.T) deals with its debentures
Medexus CEO (MDP.T) on creating Canada’s specialty pharma success story
More on MDP.T
Medexus (MDP.T) CEO explains sudden drop
Medexus Pharmaceuticals’ (MDP.T) financials are coming!
Medexus Pharma (MDP.T) is an arbitrage in the making
Medexus Pharmaceuticals (MDP.T) building serious value
Analysts say this specialty pharma stock is on track for a record $100 million USD 2023
Medexus Pharmaceuticals (MDP.T) – First Glance with Jody Vance E111